News
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
Even in This Rich Market, Gilead Sciences, Inc. Is Offering Investors Value
Major stock market indexes keep hitting record highs, but shares of Gilead Sciences, Inc. (NASDAQ: GILD) have been moving in the opposite direction. Although profits have fallen in recent....
3 Top Small-Cap Stocks to Buy in December
Small-cap stocks are riskier than their blue-chip peers, but they can also deliver incredible gains. The trick is finding solid businesses that the rest of the market is overlooking, putting your....
Alnylam Gets Some Welcome News
The FDA has agreed to allow Alnylam (NASDAQ: ALNY) and Sanofi (NYSE: SNY) to resume trials of their hemophilia therapy, fitusiran. Previously, these companies had to halt their fitusiran studies....
This Tiny Biotech Pins Hope on U.S. Approval
Amicus Therapeutics (NASDAQ: FOLD) already markets its Fabry disease drug Galafold overseas, and it hopes it will soon be able to help patients in the U.S., too. Yesterday, management reported....
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
It's been a really good year for Thermo Fisher Scientific (NYSE: TMO). The medical and laboratory instrument maker's stock is up nearly 36% so far in 2017, nearly double the increase for the....
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
It's been a really good year for Thermo Fisher Scientific (NYSE: TMO). The medical and laboratory instrument maker's stock is up nearly 36% so far in 2017, nearly double the increase for the....
Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific
It's been a really good year for Thermo Fisher Scientific (NYSE: TMO). The medical and laboratory instrument maker's stock is up nearly 36% so far in 2017, nearly double the increase for the....
What to Expect From AbbVie Inc. in 2018
In the words of the legendary James Brown, I feel good.Early this year, I bought a position in AbbVie (NYSE: ABBV). The big pharma stock is on track for 2017 to be its best year ever. And I'm....
Why Genomic Health, Inc. Skyrocketed Today
Genomic Health (NASDAQ: GHDX) is up 21% at 1:12 p.m. EST Thursday after Bloomberg reported that the cancer test company is contemplating selling itself after receiving takeover interest.While it's....
Here's Why Marinus Pharmaceuticals Is Soaring Today
Welcome to the popular clique, kid. Shares of clinical-stage biopharma Marinus Pharmaceuticals (NASDAQ: MRNS) rose as much as 22.2% by noon EST after the company announced it will be added to the....
BOIRON : Acquisition de marques et brevets
Les Laboratoires BOIRON ont acquis auprès de la société suisse ALKANTIS les marques et brevets relatifs à son dispositif médical à visée antalgique, anti-inflammatoire et anti-œdémateuse....
BOIRON : Acquisition of trademarks and patents
The BOIRON Laboratories have acquired from the Swiss company ALKANTIS the trademarks and patents relating to its medical device for analgesic, anti-inflammatory and anti-oedematous purposes....
Is the Stock Market Overpriced? Yes -- but Not These 3 Sectors
Is the stock market overpriced? Consider that the historical price-to-earnings (P/E) ratio for the S&P 500 over the past 146 years is 15.6. The current earnings multiple is over 25.5 -- more....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....
Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?
Regeneron Pharmaceuticals (NASDAQ: REGN) shares have made little headway since the disappointing launch of Praluent in 2015. Perhaps, the company's latest drug, cemiplimab, can change that.....
Why ImmunoGen, Inc. Jumped Higher Today
Shares of ImmunoGen (NASDAQ: IMGN) closed up 12% as the American Society of Hematology (ASH) meeting wraps up. The biotech presented over the weekend, which shouldn't be affecting the price of....
Is Illumina, Inc. a Buy?
2017 has been an excellent year for Illumina (NASDAQ: ILMN), the market leader for gene sequencers, having revived sales growth thanks to the rollout of a new product line. Shareholders have been....
Is Illumina, Inc. a Buy?
2017 has been an excellent year for Illumina (NASDAQ: ILMN), the market leader for gene sequencers, having revived sales growth thanks to the rollout of a new product line. Shareholders have been....
Is Illumina, Inc. a Buy?
2017 has been an excellent year for Illumina (NASDAQ: ILMN), the market leader for gene sequencers, having revived sales growth thanks to the rollout of a new product line. Shareholders have been....
Here's Why Everyone's So Excited About bluebird bio
Investors have seen bluebird bio's (NASDAQ: BLUE) share price skyrocket following impressive early-stage trial results for bb2121, a multiple myeloma gene therapy that's licensed to Celgene Corp.....
5 Biotech Buyout Candidates for 2018
With the Republican tax plan steaming through both houses of Congress, 2018 is shaping up to be a banner year in terms of consolidation for the biotechnology industry. Biopharmaceutical....
Why 2017 Was a Year to Forget for Pfizer Inc.
The S&P 500 index soared 19% in 2017 (so far). The healthcare sector performed even better, with year-to-date gains of close to 21%. Several major drugmakers completed significant....